284 related articles for article (PubMed ID: 32753690)
21. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
[TBL] [Abstract][Full Text] [Related]
22. Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity.
Brunner AM; Steensma DP
Hematol Oncol Clin North Am; 2020 Apr; 34(2):379-391. PubMed ID: 32089217
[TBL] [Abstract][Full Text] [Related]
23. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
[TBL] [Abstract][Full Text] [Related]
24. Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.
Aslan D; Garde C; Nygaard MK; Helbo AS; Dimopoulos K; Hansen JW; Severinsen MT; Treppendahl MB; Sjø LD; Grønbæk K; Kristensen LS
Oncotarget; 2016 Mar; 7(9):9951-63. PubMed ID: 26848861
[TBL] [Abstract][Full Text] [Related]
25. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
[TBL] [Abstract][Full Text] [Related]
26. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
Wang X; Song X; Yan X
Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956
[TBL] [Abstract][Full Text] [Related]
27. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
[TBL] [Abstract][Full Text] [Related]
29. [RNA splicing dysregulation in hematological malignancies].
Yoshida M; Yamauchi H; Sakumoto M; Yoshimi A
Rinsho Ketsueki; 2023; 64(7):646-653. PubMed ID: 37544725
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia.
Figg JW; Barajas JM; Obeng EA
Curr Opin Hematol; 2021 Mar; 28(2):73-79. PubMed ID: 33492002
[TBL] [Abstract][Full Text] [Related]
31. [Role of Aberrant Splicing in Pathogenesis of Myelodysplastic Syndromes-Review].
Li L; Xiao ZJ; Sun XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):617-621. PubMed ID: 28446323
[TBL] [Abstract][Full Text] [Related]
32. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
[TBL] [Abstract][Full Text] [Related]
33.
Smeets MF; Tan SY; Xu JJ; Anande G; Unnikrishnan A; Chalk AM; Taylor SR; Pimanda JE; Wall M; Purton LE; Walkley CR
Blood; 2018 Aug; 132(6):608-621. PubMed ID: 29903888
[TBL] [Abstract][Full Text] [Related]
34. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M;
Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920
[TBL] [Abstract][Full Text] [Related]
35. ZRSR1 co-operates with ZRSR2 in regulating splicing of U12-type introns in murine hematopoietic cells.
Madan V; Cao Z; Teoh WW; Dakle P; Han L; Shyamsunder P; Jeitany M; Zhou S; Li J; Nordin HBM; Shi J; Yu S; Yang H; Hossain MZ; Chng WJ; Koeffler HP
Haematologica; 2022 Mar; 107(3):680-689. PubMed ID: 33691379
[TBL] [Abstract][Full Text] [Related]
36. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms.
Przychodzen B; Jerez A; Guinta K; Sekeres MA; Padgett R; Maciejewski JP; Makishima H
Blood; 2013 Aug; 122(6):999-1006. PubMed ID: 23775717
[TBL] [Abstract][Full Text] [Related]
37. Biological relevance of alternative splicing in hematologic malignancies.
Szelest M; Giannopoulos K
Mol Med; 2024 May; 30(1):62. PubMed ID: 38760666
[TBL] [Abstract][Full Text] [Related]
38. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
39. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
Nguyen HD; Leong WY; Li W; Reddy PNG; Sullivan JD; Walter MJ; Zou L; Graubert TA
Cancer Res; 2018 Sep; 78(18):5363-5374. PubMed ID: 30054334
[TBL] [Abstract][Full Text] [Related]
40. The eukaryotic translation initiation factor eIF4E reprograms alternative splicing.
Ghram M; Morris G; Culjkovic-Kraljacic B; Mars JC; Gendron P; Skrabanek L; Revuelta MV; Cerchietti L; Guzman ML; Borden KLB
EMBO J; 2023 Apr; 42(7):e110496. PubMed ID: 36843541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]